{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:06:49Z","timestamp":1778821609575,"version":"3.51.4"},"reference-count":74,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jtha.2025.07.019","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:56:50Z","timestamp":1753372610000},"page":"3654-3664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The history and historical treatments of deep vein thrombosis: toward the era of new anticoagulants"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2705-3615","authenticated-orcid":false,"given":"Jean-Philippe","family":"Galanaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Righini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.07.019_bib1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/jth.12127","article-title":"The history and historical treatments of deep vein thrombosis","volume":"11","author":"Galanaud","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2 Suppl","key":"10.1016\/j.jtha.2025.07.019_bib2","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.07.019_bib3","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1093\/eurheartj\/ehx003","article-title":"Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function","volume":"39","author":"Mazzolai","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.07.019_bib4","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.07.019_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012-2021","volume":"166","author":"Stevens","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.07.019_bib6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(46)91429-8","article-title":"Thrombosis; early diagnosis and abortive treatment with heparin","volume":"1","author":"Bauer","year":"1946","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.07.019_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial","volume":"1","author":"Barritt","year":"1960","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.07.019_bib8","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/cells11203214","article-title":"Anticoagulants: a short history, their mechanism of action, pharmacology, and indications","volume":"11","author":"Heestermans","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jtha.2025.07.019_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0049-3848(88)90279-4","article-title":"The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity","volume":"51","author":"Walenga","year":"1988","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.07.019_bib10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"B\u00fcller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.07.019_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1538-7836.2003.00034.x","article-title":"A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I","volume":"1","author":"Eriksson","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.019_bib15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib16","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Buller","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4059","article-title":"Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010-2020","volume":"6","author":"Iyer","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2 Suppl","key":"10.1016\/j.jtha.2025.07.019_bib20","doi-asserted-by":"crossref","first-page":"26s","DOI":"10.1378\/chest.89.2_Supplement.26S","article-title":"Antithrombotic therapy for venous thromboembolic disease","volume":"89","author":"Hyers","year":"1986","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.07.019_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.CIR.12.4.553","article-title":"Studies in intravascular coagulation. IV. The effect of heparin and dicumarol on serum-induced venous thrombosis","volume":"12","author":"Wessler","year":"1955","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.07.019_bib22","first-page":"2971285","article-title":"Anticoagulants in venous thromboembolism","author":"Fennerty","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2025.07.019_bib23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJM197910183011602","article-title":"Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis","volume":"301","author":"Hull","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib24","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJM198610303151801","article-title":"Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis","volume":"315","author":"Hull","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(86)91431-5","article-title":"Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism","volume":"2","author":"Gallus","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.07.019_bib26","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199005033221802","article-title":"Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis","volume":"322","author":"Hull","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib27","first-page":"433","article-title":"The anti-coagulants: heparin and the dicoumarin-3, 3' methylene-bis-(4-hydroxycoumarin)","volume":"18","author":"Prandoni","year":"1942","journal-title":"Bull N Y Acad Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib28","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199211193272103","article-title":"Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis","volume":"327","author":"Brandjes","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1365-2168.2000.01352.x","article-title":"Warfarin induced skin necrosis","volume":"87","author":"Chan","year":"2000","journal-title":"Br J Surg"},{"key":"10.1016\/j.jtha.2025.07.019_bib30","first-page":"1121","article-title":"Thrombophlebitis migrans disseminata: report of a case in which gangrene of a breast occurred. Observations on the therapeutic use of dicumarol","volume":"43","author":"Flood","year":"1943","journal-title":"N Y State J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.0954-6820.1954.tb01741.x","article-title":"Local haemorrhage and necrosis of the skin and underlying tissues, during anti-coagulant therapy with dicumarol or dicumacyl","volume":"148","author":"Verhagen","year":"1954","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.jtha.2025.07.019_bib32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1538-7836.2003.00516.x","article-title":"A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation","volume":"2","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.019_bib34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1538-7836.2010.03746.x","article-title":"Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion","volume":"8","author":"Paty","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.019_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2010.04100.x","article-title":"Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis","volume":"9","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.019_bib36","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jth.12546","article-title":"Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study","volume":"12","author":"Buller","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.019_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","author":"Bousser","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.07.019_bib38","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib39","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.jtha.2024.05.013","article-title":"The historical origins of modern international normalized ratio targets","volume":"22","author":"Raza","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.019_bib40","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib42","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0140-6736(49)91829-2","article-title":"Aspirin in the treatment of vascular diseases","volume":"2","author":"Gibson","year":"1949","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.07.019_bib43","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib44","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib46","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib47","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.07.019_bib48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.7326\/0003-4819-25-6-941","article-title":"Dicoumarol therapy","volume":"25","author":"Levan","year":"1946","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib49","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00000658-196910000-00007","article-title":"Assessment of anticoagulant treatment of venous thromboembolism","volume":"170","author":"Coon","year":"1969","journal-title":"Ann Surg"},{"key":"10.1016\/j.jtha.2025.07.019_bib50","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.5694\/j.1326-5377.1972.tb103752.x","article-title":"Duration of anticoagulant therapy in venous thromboembolism","volume":"2","author":"O\u2019Sullivan","year":"1972","journal-title":"Med J Aust"},{"key":"10.1016\/j.jtha.2025.07.019_bib51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.0954-6820.1985.tb06125.x","article-title":"One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis","volume":"218","author":"Holmgren","year":"1985","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.jtha.2025.07.019_bib52","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.0954-6820.1985.tb03261.x","article-title":"The duration of oral anticoagulation after deep vein thrombosis. A randomized study","volume":"217","author":"Schulman","year":"1985","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.jtha.2025.07.019_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2257.1987.tb01377.x","article-title":"A comparison of 3 and 6 weeks\u2019 anticoagulation in the treatment of venous thromboembolism","volume":"9","author":"Fennerty","year":"1987","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.jtha.2025.07.019_bib54","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2165\/00003495-198530050-00004","article-title":"Risk of haemorrhage associated with long term anticoagulant therapy","volume":"30","author":"Levine","year":"1985","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2025.07.019_bib55","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0140-6736(92)93285-U","article-title":"Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society","volume":"340","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.07.019_bib56","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1055\/s-0038-1649783","article-title":"Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis","volume":"74","author":"Levine","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.019_bib57","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1056\/NEJM199506223322501","article-title":"A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group","volume":"332","author":"Schulman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib58","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism","volume":"340","author":"Kearon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators","volume":"345","author":"Agnelli","year":"2001","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"10.1016\/j.jtha.2025.07.019_bib60","doi-asserted-by":"crossref","first-page":"454s","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.07.019_bib61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.07.019_bib62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000073567","article-title":"Venous thrombosis: the history of knowledge","volume":"32","author":"Mannucci","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jtha.2025.07.019_bib63","first-page":"188","article-title":"Oblit\u00e9ration des veines et de son influence sur la formation des hydropsies partielles: consid\u00e9ration sur les hydropisies passive et general","volume":"1","author":"Bouillard","year":"1823","journal-title":"Arch Gen Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/cancers11020158","article-title":"The history of Armand Trousseau and cancer-associated thrombosis","volume":"11","author":"Metharom","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtha.2025.07.019_bib65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib66","doi-asserted-by":"crossref","DOI":"10.4081\/reumatismo.2022.1556","article-title":"The history of antiphospholipid syndrome","volume":"74","author":"Tincani","year":"2023","journal-title":"Reumatismo"},{"key":"10.1016\/j.jtha.2025.07.019_bib67","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/bmj.287.6399.1088","article-title":"Thrombosis, abortion, cerebral disease, and the lupus anticoagulant","volume":"287","author":"Hughes","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jtha.2025.07.019_bib68","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.07.019_bib69","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.019_bib70","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.07.019_bib71","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.019_bib72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib73","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib74","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.019_bib75","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jtha.2022.12.019","article-title":"Machine learning in the coagulation and hemostasis arena: an overview and evaluation of methods, review of literature, and future directions","volume":"21","author":"Rashidi","year":"2023","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:09:17Z","timestamp":1778818157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625004696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":74,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1538783625004696"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.07.019","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The history and historical treatments of deep vein thrombosis: toward the era of new anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}